Association of brain-derived neurotrophic factor (BDNF) haploinsufficiency with lower adaptive behaviour and reduced cognitive functioning in WAGR/11p13 deletion syndrome.

In animal studies, brain-derived neurotrophic factor (BDNF) is an important regulator of central nervous system development and synaptic plasticity. WAGR (Wilms tumour, Aniridia, Genitourinary anomalies, and mental Retardation) syndrome is caused by 11p13 deletions of variable size near the BDNF locus and can serve as a model for studying human BDNF haploinsufficiency (+/-). We hypothesized that BDNF+/- would be associated with more severe cognitive impairment in subjects with WAGR syndrome. Twenty-eight subjects with WAGR syndrome (6-28 years), 12 subjects with isolated aniridia due to PAX6 mutations/microdeletions (7-54 years), and 20 healthy controls (4-32 years) received neurocognitive assessments. Deletion boundaries for the subjects in the WAGR group were determined by high-resolution oligonucleotide array comparative genomic hybridization. Within the WAGR group, BDNF+/- subjects (n = 15), compared with BDNF intact (+/+) subjects (n = 13), had lower adaptive behaviour (p = .02), reduced cognitive functioning (p = .04), higher levels of reported historical (p = .02) and current (p = .02) social impairment, and higher percentage meeting cut-off score for autism (p = .047) on Autism Diagnostic Interview-Revised. These differences remained nominally significant after adjusting for visual acuity. Using diagnostic measures and clinical judgement, 3 subjects (2 BDNF+/- and 1 BDNF+/+) in the WAGR group (10.7%) were classified with autism spectrum disorder. A comparison group of visually impaired subjects with isolated aniridia had cognitive functioning comparable to that of healthy controls. In summary, among subjects with WAGR syndrome, BDNF+/- subjects had a mean Vineland Adaptive Behaviour Compose score that was 14-points lower and a mean intelligence quotient (IQ) that was 20-points lower than BDNF+/+ subjects. Our findings support the hypothesis that BDNF plays an important role in human neurocognitive development.
AuthorsJoan C Han, Audrey Thurm, Christine Golden Williams, Lisa A Joseph, Wadih M Zein, Brian P Brooks, John A Butman, Sheila M Brady, Shannon R Fuhr, Melanie D Hicks, Amanda E Huey, Alyson E Hanish, Kristen M Danley, Margarita J Raygada, Owen M Rennert, Keri Martinowich, Stephen J Sharp, Jack W Tsao, Susan E Swedo
JournalCortex; a journal devoted to the study of the nervous system and behavior (Cortex) 2013 Nov-Dec Vol. 49 Issue 10 Pg. 2700-10 ISSN: 1973-8102 [Electronic] Italy
PMID23517654 (Publication Type: Journal Article, Research Support, N.I.H., Intramural)
CopyrightPublished by Elsevier Ltd.
Chemical References
  • Brain-Derived Neurotrophic Factor
  • brain-derived neurotrophic factor, human
  • Adaptation, Psychological (physiology)
  • Adolescent
  • Adult
  • Aniridia (complications, genetics)
  • Autistic Disorder (genetics, psychology)
  • Behavior (physiology)
  • Brain (pathology)
  • Brain-Derived Neurotrophic Factor (deficiency)
  • Child
  • Child Behavior Disorders (etiology, psychology)
  • Child, Preschool
  • Chromosome Deletion
  • Chromosome Mapping
  • Chromosomes, Human, Pair 11 (genetics)
  • Cognition (physiology)
  • Cognition Disorders (genetics, physiopathology, psychology)
  • Cohort Studies
  • Corpus Callosum (pathology)
  • Female
  • Haploinsufficiency (genetics, physiology)
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Vision Tests
  • Visual Acuity
  • WAGR Syndrome (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: